Drug Profile
AR 105
Alternative Names: Aerubumab; Aerucin; AR-105; CM 101 - Aridis Pharmaceuticals; CM101; F 429Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Kenta Biotech
- Developer Aridis Pharmaceuticals
- Class Antibacterials; Antifibrotics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Nosocomial pneumonia
- Discontinued Cystic fibrosis
Most Recent Events
- 09 Feb 2024 Pipeline push - Updated indication to nosocomial pneumonia as per pipeline mentions hospital and ventilator acquired pneumonia
- 31 Dec 2020 Aridis Pharmaceuticals in-licenses patents for AR 105 from The Brigham and Women's Hospital
- 31 Dec 2020 AAR 105 is still in phase II trials for Pneumonia USA, Spain, Poland, Hungary, Greece, Germany, Czech Republic and Belgium (IV)